Your browser doesn't support javascript.
loading
Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter.
Fong, Sylvia; Handyside, Britta; Sihn, Choong-Ryoul; Liu, Su; Zhang, Lening; Xie, Lin; Murphy, Ryan; Galicia, Nicole; Yates, Bridget; Minto, Wesley C; Vitelli, Catherine; Harmon, Danielle; Ru, Yuanbin; Yu, Guoying Karen; Escher, Claudia; Vowinckel, Jakob; Woloszynek, Jill; Akeefe, Hassib; Mahimkar, Rajeev; Bullens, Sherry; Bunting, Stuart.
Afiliação
  • Fong S; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Handyside B; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Sihn CR; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Liu S; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Zhang L; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Xie L; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Murphy R; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Galicia N; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Yates B; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Minto WC; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Vitelli C; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Harmon D; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Ru Y; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Yu GK; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Escher C; Biognosys AG, Schlieren, Switzerland.
  • Vowinckel J; Biognosys AG, Schlieren, Switzerland.
  • Woloszynek J; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Akeefe H; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Mahimkar R; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Bullens S; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
  • Bunting S; BioMarin Pharmaceutical, Inc., Novato, CA, USA.
Mol Ther Methods Clin Dev ; 18: 620-630, 2020 Sep 11.
Article em En | MEDLINE | ID: mdl-32775496
ABSTRACT
Adeno-associated virus 5 (AAV5)-human factor VIII-SQ (hFVIII-SQ; valoctocogene roxaparvovec) is an AAV-mediated product under evaluation for treatment of severe hemophilia A, which contains a B-domain-deleted hFVIII (hFVIII-SQ) transgene and a hybrid liver-specific promotor (HLP). To increase FVIII-SQ expression and reduce the vector dose required, a stronger promoter may be considered. However, because FVIII-SQ is a protein known to be difficult to fold and secrete, this could potentially induce endoplasmic reticulum (ER) stress. We evaluated the effect of two AAV5-hFVIII-SQ vectors with different liver-specific promoter strength (HLP << 100ATGB) on hepatic ER stress in mice. Five weeks after receiving vehicle or vector, the percentage of transduced hepatocytes and levels of liver hFVIII-SQ DNA and RNA increased dose dependently for both vectors. At lower doses, plasma hFVIII-SQ protein levels were higher for 100ATGB. This difference was attenuated at the highest dose. For 100ATGB, liver hFVIII-SQ protein accumulated dose dependently, with increased expression of ER stress markers at the highest dose, suggesting hepatocytes reached or exceeded their capacity to fold/secrete hFVIII-SQ. These data suggest that weaker promoters may require relatively higher doses to distribute expression load across a greater number of hepatocytes, whereas relatively stronger promoters may produce comparable levels of FVIII in fewer hepatocytes, with potential for ER stress.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article